# Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Article · Patrick Mahlen O'Neil, Andreas L. Birkenfeld, Barbara M. McGowan, Ofri Mosenzon, Sue D. Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P.H. Wilding

- Archive id: doi:10.1016/s0140-6736(18)31773-2
- Published: 2018-08-01
- Venue: The Lancet
- DOI: https://doi.org/10.1016/s0140-6736(18)31773-2
- PMID: 30122305
- Citations: 813
- Source URL: https://doi.org/10.1016/s0140-6736(18)31773-2
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.